Abstract:Background Effective disease surveillance, including that for COVID-19, is compromised without a standardised method for categorising the immunosuppressed as a clinical risk group. Methods We conducted a systematic review and meta-analysis to evaluate whether excess COVID-associated mortality compared to the immunocompetent could meaningfully subdivide the immunosuppressed. Our study adhered to UK Immunisation against infectious disease (Green Book) criteria for defining and categorising immunosuppression. Using OVID (EMBASE, MEDLINE, Transplant Library, and Global Health), PubMed, and Google Scholar, we examined relevant literature between the entirety of 2020 and 2022. We selected for cohort studies that provided mortality data for immunosuppressed subgroups and immunocompetent controls. Meta-analyses, grey literature and any original works that failed to provide comparator data or reported all-cause or paediatric outcomes were excluded. Odds Ratios (OR) and 95% confidence intervals (CI) of COVID-19 mortality were meta-analysed by immunosuppressed category and subcategory. Subgroup analyses differentiated estimates by effect measure, country income, study setting, level of adjustment, use of matching and publication year. Study screening, extraction and bias assessment were performed blinded and independently by two researchers; conflicts were resolved with the oversight of a third researcher. PROSPERO registration number is CRD42022360755. Findings We identified 99 unique studies, incorporating data from 1,542,097 and 56,248,181 unique immunosuppressed and immunocompetent patients with COVID-19 infection, respectively. Compared to immunocompetent people (pooled OR, 95%CI), solid organ transplants (2.12, 1.50-2.99) and malignancy (2.02, 1.69-2.42) patients had a very high risk of COVID-19 mortality. Patients with rheumatological conditions (1.28, 1.13-1.45) and HIV (1.20, 1.05-1.36) had just slightly higher risks than the immunocompetent baseline. Case type, setting income and mortality data matching and adjustment were significant modifiers of excess immunosuppressed mortality for some immunosuppressed subgroups. Interpretation Excess COVID-associated mortality among the immunosuppressed compared to immunocompetent was seen to vary significantly across subgroups. This novel means of subdivision has prospective benefit for targeting patient triage, shielding and vaccination policies during periods of high disease transmission. Funding Supported by EMIS Health and the UK Medical Research Council. Grant number: MR/R015708/1.

Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: Systematic review and meta-analysis

Immunosuppressants in Liver Transplant Recipients With Coronavirus Disease 2019: Capability or Catastrophe?-A Systematic Review and Meta-Analysis

Impact of solid organ transplant status on outcomes of hospitalized patients with COVID‐19 infection

Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients

Long‐term outcomes after COVID‐19 infection in transplant recipients

Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study

The association between severe or death COVID-19 and solid organ transplantation: A systematic review and meta-analysis

Clinical Outcomes of Solid Organ Transplant Recipients Hospitalized with COVID-19: A Propensity Score-Matched Cohort Study

Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023

Adequacy to immunosuppression management guidelines in kidney transplant recipients with severe COVID-19 pneumonia: a practice survey

The burden of COVID-19 mortality among solid organ transplant recipients in the United States

Risk factors for SARS-CoV-2 infection and severe COVID-19 in unvaccinated solid organ transplant recipients

Clinical outcomes for COVID-19 in lung transplant recipients (LTRs): an insight from the early Omicron wave

Impact of immunosuppression on the immune response to SARS-CoV-2 infection: A mechanistic study

Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients

Corticosteroid Therapy in Critically Ill Patients with COVID-19: a Multicenter, Retrospective Study

The Relative Risk of COVID-19 in Solid Organ Transplant Recipients Over Waves of the Pandemic

Impact of Immunosuppressants and Vaccination on COVID-19 Outcomes in Autoimmune Patients and Solid Organ Transplant Recipients: A Nationwide Propensity Score-Matched Study

Optimal Duration of Systemic Corticosteroids in Coronavirus Disease 2019 Treatment: A Systematic Review and Meta-analysis

Disparities in COVID-19 Mortality Amongst the Immunosuppressed: A Systematic Review and Meta-analysis for Enhanced Disease Surveillance

Delayed mortality among solid organ transplant recipients hospitalized for COVID-19